Abstract: The invention discloses methods for the chronic administration of adenosine, which contrary to the acute delivery of the drug by injection or infusion, acts in desensitizing adenosine receptors towards the action of adenosine. The methods and oral compositions of adenosine triphosphate (ATP), which is degraded to adenosine in vivo, can be used in the treatment of disorders and diseases that are therapeutically targeted by agonists or antagonists of adenosine receptors. One example is the stimulation of lipolysis in achieving weight loss in humans and in the treatment of obesity.
Abstract: A method of treating palmar and plantar fibromatosis is disclosed. The method includes administering to a patient of a therapeutically effective amount of a composition comprising 13-cis-retinoic acid. Preferably, the treatment method includes administering to a patient of an initial dosage of a composition comprising 13-cis-retinoic acid for an initial treatment period, and thereafter administering a maintenance dosage of the composition.
Abstract: A deodorant or antiperspirant soft solid composition is filled into dispensing containers by injection moulding, i.e. under pressure, preferably in the vicinity of its normal setting temperature. The deodorant or antiperspirant composition is preferably continuously produced in a screw extruder, especially a twin screw extruder, controlled to deliver the composition in a suitably viscous state under low shear and particularly for formulations in which a particulate antiperspirant is suspended in a fluid carrier. The pressure in the injection head at the point of injection is greater than 120 kPa and in many instances from 800 to 2000 kPa. The combined process offers benefits for controlled fill of dispensing containers, particularly for formulations incorporating sensitive ingredients and offers tolerance in composition temperature at the time of fill.
Type:
Grant
Filed:
April 5, 2001
Date of Patent:
March 9, 2004
Assignee:
Unilever Home & Personal Care USA, division of Conopco,
Inc.
Inventors:
Peter Stewart Allan, Michael Andrew Browne, Elfriede Maria Langeveld, Paul Lloyd, Reginald Manley, Paul Reissen Rennie, Frederick Edmund Stocker, Karnik Tarverdi, Jacqueline Marie Thorpe
Abstract: Novel crystalline forms of Fluvastatin sodium hydrates were found, referred to hereinafter as polymorphic Forms C, D, E and F. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms, a process for the preparation of highly crystalline Fluvastatin sodium Form A, and pharmaceutical compositions comprising the crystalline forms.
Type:
Grant
Filed:
July 30, 2002
Date of Patent:
February 24, 2004
Assignee:
Ciba Specialty Chemicals Corporation
Inventors:
Paul Adriaan Van Der Schaaf, Claudia Marcolli, Martin Szelagiewicz, Andreas Burkhard, Heinz Wolleb, Annemarie Wolleb
Abstract: The invention relates to hair compositions packaged in aerosol form and comprising, in a cosmetically acceptable medium, a polycondensate, such as a multiblock polymer, comprising at least one polyurethane and/or polyurea unit, at least one polyol, an organic solvent, and a propellant gas. The invention is also directed towards a process for shaping or maintaining the hairstyle, comprising the use of these compositions, as well as to their use for the manufacture of hair products, in order to maintain or shape the hairstyle.
Abstract: A carbon dioxide-containing viscous composition wherein carbon dioxide bubbles are retained in an aqueous viscous composition. Use of the composition makes it possible to treat or ameliorate itching accompanying mucocutaneous diseases or mucocutaneous disorders, mucocutaneous injury, dental diseases, skin ulcer, cryesthesia and numbness caused by peripheral circulatory disorders, musculoskeletal diseases, nervous system diseases, keratosis, constipation, unwanted hair re-growing after depilation, cosmetic troubles in the skin or hair, partial obesity, etc. while exerting little side effects.
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule in an amount sufficient to control the aberrant growth state e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity. The present invention further makes available methods and reagents for ameliorating to consequences of hedgehog loss-of-function, ptc gain-of-function, or smoothened loss-of-function comprising contacting a cell with a compound, such as a polypeptide or small molecule, in an amount sufficient to ameliorate the In certain embodiments, the subject compounds, e.g., a cAMP analog, adenylate cyclase agonist, or cAMP phosphodiesterase inhibitor, regulate cAMP levels, which in turn modulates activity of the hedgehog pathway.
Abstract: The present invention relates to a dermatologic preparation containing a diamide derivative represented by the following formula (1):
(wherein, R1 represents a linear or branched hydrocarbon group having 1 to 22 carbon atoms which may be substituted by one or more hydroxy and/or alkoxy groups, R2 represents a linear or branched divalent hydrocarbon group having 1 to 12 carbon atoms, and R3 represents a linear or branched divalent hydrocarbon group having 1 to 42 carbon atoms). This diamide derivative (1) is capable of fundamentally improving the water retention capacity and barrier functions of the horny layer, is excellent in miscibility and mixing stability and can be prepared efficiently at a low cost.
Abstract: The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.
Type:
Grant
Filed:
March 26, 2002
Date of Patent:
February 3, 2004
Assignee:
Council of Scientific and Industrial Research
Inventors:
Ghulam Nabi Qazi, Bupinder Singh Jaggi, Bal Krishan Chandan, Krishnan Avtar Suri, Naresh Kumar Satti, Rakesh Maurya, Lila Ram Manhas, Ashwani Kumar, Bal Krishnan Kapahi
Abstract: The invention provides for methods of monitoring the proliferation of cultured prostate cancer cells in the presence of omega-3 fatty acids, methods of treating an individual with prostate cancer or at risk of developing prostate cancer, and methods of reducing the risk of recurrence of prostate cancer in an individual who had previously been treated for prostate cancer. Methods of the invention further include treating an individual with benign prostatic hyperplasia (BPH) with omega-3 fatty acids as well as methods of screening for compounds that inhibit the proliferation of prostate cancer cells. The invention provides for compositions and articles of manufacture containing omega-3 fatty acids in particular formulations, and omega-3 fatty acids with a second compound that also exerts an effect on the androgen receptor.
Type:
Grant
Filed:
September 20, 2001
Date of Patent:
December 2, 2003
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The present invention includes a cosmetic formulation. The cosmetic formulation comprises a plurality of spheres having a first desiccated volume and having a second hydrated volume. The hydrated volume is greater than the desiccated volume.
Type:
Grant
Filed:
September 17, 2002
Date of Patent:
November 18, 2003
Assignee:
Coty Inc.
Inventors:
Salvatore Barone, Antonietta Corrigan, Mita Mody, Melizza Bautista, Ralph Macchio, Louis Veltry
Abstract: The present invention relates to compositions comprising S-tofisopam substantially free of R-tofisopam, and methods for treating or preventing convulsions and/or seizures comprising administration of the composition to subjects in need of treatment therefor. Also provided are compositions and methods for treating or preventing convulsions and/or seizures comprising administering S-tofisopam substantially free of R-tofisopam with another anti-convulsant.
Abstract: The first embodiment of the present invention provides a composition, which includes:
at least one aqueous phase that includes an aqueous suspension of particles of an at least partially crosslinked organopolysiloxane elastomer; and
at least one sugar or sugar derivative. Other embodiments of the invention provide for the use of the above-described composition. Another embodiment of the invention provides a method selected from the group including treating, protecting, caring for, removing make-up from, and cleaning at least one selected from the group including the skin, lips and hair, and combinations thereof, which method includes applying the above-described composition to the skin, lips or hair.
Abstract: Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of alcoholism. Said substances are administered preferably in a continuos and controlled manner. The pharmaceutical administration form enables controlled release, e.g. for oral, transdermal or another route of parenteral administration.
Type:
Grant
Filed:
July 25, 2001
Date of Patent:
September 30, 2003
Assignees:
LTS Lohmann Therapie-Systeme AG, He Arzneimittelforschung GmbH
Inventors:
Bodo Asmussen, Thomas Hille, Hans-Rainer Hoffmann, Klaus Opitz
Abstract: A composition for use in bleaching hair in combination with a liquid peroxide based oxidizing agent, said composition comprising an effective amount of at least one persulfate salt dispersed in a silicone oil base and a method for bleaching hair with said composition.
Abstract: Mucosal adjuvants for vaccines contain water-soluble polyanionic polymers which have anionic constitutional units obtained from acids such as acrylic acid, methacrylic acid, maleic acid, fumaric acid, ethylsulphonic acid, vinylsulphuric acid, vinylsulphonic acid, styrenesulphonic acid, vinylphenylsulphuric acid, 2-methacryloyloxyethane sulphonic acid, 3-methacryloyloxy-2-hydroxypropanesulphonic acid, 3-methacryl amido-3-methylbutanoic acid, acrylamidomethylpropanesulphonic acid, vinylphosphoric acid, 4-vinylbenzoic acid, 3-vinyl oxypropane-1-sulphonic acid, N-vinylsuccinimidic acid, and salts of the foregoing. The polyanionic polymers may further have hydrophobic constitutional repeating units, such as alkylesters, cycloalkylesters, hydroxyalkylesters, ethers, glycols, aromatic groups and salts thereof. The adjuvants containing the polyanionic polymers are used in vaccines for the induction or enhancement of mucosal immune responses.
Abstract: Disclosed is a composition including a lower alcohol and water in a weight ratio of about 35:65 to 100:0, between at least 0.5% and 8.0% by weight thickener system comprised of at least two emulsifiers, each emulsifier present in at least 0.05% by weight wherein the composition free of auxiliary thickeners has a viscosity of at least 4,000 centipoise at 23° C. and wherein each emulsifier is comprised of at least one hydrophobic group and at least one hydrophilic group. The composition is useful as a presurgical scrub replacement, a lotion or other hand preparation.
Type:
Grant
Filed:
February 14, 2002
Date of Patent:
August 26, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Matthew T. Scholz, Robert A. Asmus, Jill R. Charpentier
Abstract: The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.
Type:
Grant
Filed:
May 3, 2001
Date of Patent:
August 19, 2003
Assignee:
Pfizer Inc
Inventors:
Stafford McLean, Stevin H. Zorn, Elisa R. Jackson
Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z), 14(Z)-dienoic acid and 20-, 21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z), 15(Z)-dienoic acid.
Type:
Grant
Filed:
December 14, 2001
Date of Patent:
August 12, 2003
Assignee:
MCW Research Foundation
Inventors:
Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder